ADC Therapeutics (ADCT) EPS (Basic) (2020 - 2023)
Historic EPS (Basic) for ADC Therapeutics (ADCT) over the last 4 years, with Q3 2023 value amounting to -$0.57.
- ADC Therapeutics' EPS (Basic) fell 10000.19% to -$0.57 in Q3 2023 from the same period last year, while for Sep 2023 it was -$0.0, marking a year-over-year decrease of 10000.0%. This contributed to the annual value of -$0.0 for FY2022, which is 3535.06% up from last year.
- Latest data reveals that ADC Therapeutics reported EPS (Basic) of -$0.57 as of Q3 2023, which was down 10000.19% from -$0.6 recorded in Q2 2023.
- Over the past 5 years, ADC Therapeutics' EPS (Basic) peaked at $76906.0 during Q1 2021, and registered a low of -$80.31 during Q1 2023.
- Its 4-year average for EPS (Basic) is $29773.4, with a median of $28913.9 in 2021.
- As far as peak fluctuations go, ADC Therapeutics' EPS (Basic) skyrocketed by 32650.8% in 2021, and later tumbled by 10010.6% in 2023.
- Over the past 4 years, ADC Therapeutics' EPS (Basic) (Quarter) stood at $6578.6 in 2020, then tumbled by 100.0% to -$0.0 in 2021, then soared by 32.93% to -$0.0 in 2022, then crashed by 189758.36% to -$0.57 in 2023.
- Its EPS (Basic) stands at -$0.57 for Q3 2023, versus -$0.6 for Q2 2023 and -$80.31 for Q1 2023.